期刊
CURRENT DRUG TARGETS
卷 18, 期 15, 页码 1712-1721出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450117666160401120308
关键词
Myocardial infarction; myocardial reperfusion injury; ischemic conditioning; cardiac pharmacology; clinical trial
资金
- National Basic Research Program [2014CB542302]
- International S&T Cooperation Program of China [2013DFB30310]
- Natural Science Foundation of China [811170244, 81222001, 81470541]
- Capital University of Medical Sciences Foundation for Basic and Clinical Research [16JL27]
- Beijing Health System High Level Health Technology Talent Cultivation Plan open Foundation from Beijing Key Laboratory of Hypertension Research [2015-3-028]
Background: Experimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored. Objective: To discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury. Results: Existing therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide. Conclusion: Studies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据